Staar Surgical Co (STAA)

$47.82

-0.37

(-0.77%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Staar Surgical Co

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 92.30M → 76.27M (in $), with an average decrease of 9.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 4.81M → 7.75M (in $), with an average increase of 37.9% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 27.1% return, outperforming this stock by 57.1%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 28.5% return, outperforming this stock by 92.8%

Performance

  • $47.77
    $49.08
    $47.82
    downward going graph

    0.1%

    Downside

    Day's Volatility :2.67%

    Upside

    2.57%

    downward going graph
  • $26.66
    $73.13
    $47.82
    downward going graph

    44.25%

    Downside

    52 Weeks Volatility :63.54%

    Upside

    34.61%

    downward going graph

Returns

PeriodStaar Surgical CoSector (Health Care)Index (Russel 2000)
3 Months
61.17%
1.7%
0.0%
6 Months
23.34%
11.3%
0.0%
1 Year
-29.99%
5.4%
1.3%
3 Years
-64.7%
13.9%
-22.1%

Highlights

Market Capitalization
2.4B
Book Value
$7.91
Earnings Per Share (EPS)
0.43
PE Ratio
112.07
PEG Ratio
-4.89
Wall Street Target Price
48.28
Profit Margin
6.62%
Operating Margin TTM
15.55%
Return On Assets TTM
4.09%
Return On Equity TTM
5.91%
Revenue TTM
322.4M
Revenue Per Share TTM
6.65
Quarterly Revenue Growth YOY
19.1%
Gross Profit TTM
223.4M
EBITDA
34.8M
Diluted Eps TTM
0.43
Quarterly Earnings Growth YOY
0.22
EPS Estimate Current Year
1.04
EPS Estimate Next Year
0.91
EPS Estimate Current Quarter
0.17
EPS Estimate Next Quarter
0.16

Analyst Recommendation

Buy
    58%Buy
    41%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Staar Surgical Co(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
12
Hold
7
8
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 0.96%

Current $47.82
Target $48.28

Company Financials

FY19Y/Y Change
Revenue
124.0M
↑ 36.8%
Net Income
5.0M
↓ 332.26%
Net Profit Margin
4.01%
↑ 6.37%
FY20Y/Y Change
Revenue
150.2M
↑ 21.16%
Net Income
14.0M
↑ 182.77%
Net Profit Margin
9.35%
↑ 5.34%
FY21Y/Y Change
Revenue
163.5M
↑ 8.84%
Net Income
5.9M
↓ 57.91%
Net Profit Margin
3.62%
↓ 5.73%
FY22Y/Y Change
Revenue
230.5M
↑ 41.0%
Net Income
27.5M
↑ 365.26%
Net Profit Margin
11.94%
↑ 8.32%
FY23Y/Y Change
Revenue
284.4M
↑ 23.4%
Net Income
39.7M
↑ 44.18%
Net Profit Margin
13.95%
↑ 2.01%
FY24Y/Y Change
Revenue
322.4M
↑ 13.37%
Net Income
21.3M
↓ 46.18%
Net Profit Margin
6.62%
↓ 7.33%
Q4 FY22Q/Q Change
Revenue
76.0M
↓ 6.23%
Net Income
10.3M
↓ 21.29%
Net Profit Margin
13.49%
↓ 2.59%
Q1 FY23Q/Q Change
Revenue
64.0M
↓ 15.78%
Net Income
5.9M
↓ 42.96%
Net Profit Margin
9.14%
↓ 4.35%
Q2 FY23Q/Q Change
Revenue
73.5M
↑ 14.81%
Net Income
2.7M
↓ 53.7%
Net Profit Margin
3.69%
↓ 5.45%
Q3 FY23Q/Q Change
Revenue
92.3M
↑ 25.54%
Net Income
6.1M
↑ 123.76%
Net Profit Margin
6.57%
↑ 2.88%
Q4 FY23Q/Q Change
Revenue
80.3M
↓ 13.0%
Net Income
4.8M
↓ 20.56%
Net Profit Margin
6.0%
↓ 0.57%
Q1 FY24Q/Q Change
Revenue
76.3M
↓ 5.02%
Net Income
7.8M
↑ 61.01%
Net Profit Margin
10.17%
↑ 4.17%
FY19Y/Y Change
Total Assets
167.3M
↑ 146.33%
Total Liabilities
34.9M
↑ 39.67%
FY20Y/Y Change
Total Assets
206.9M
↑ 23.62%
Total Liabilities
47.0M
↑ 34.57%
FY21Y/Y Change
Total Assets
257.4M
↑ 24.44%
Total Liabilities
60.2M
↑ 28.12%
FY22Y/Y Change
Total Assets
345.8M
↑ 34.33%
Total Liabilities
87.2M
↑ 44.9%
FY23Y/Y Change
Total Assets
415.1M
↑ 20.06%
Total Liabilities
82.7M
↓ 5.18%
FY24Y/Y Change
Total Assets
488.7M
↑ 17.72%
Total Liabilities
102.7M
↑ 24.22%
Q4 FY22Q/Q Change
Total Assets
394.7M
↑ 4.96%
Total Liabilities
74.5M
↓ 2.83%
Q1 FY23Q/Q Change
Total Assets
415.1M
↑ 5.19%
Total Liabilities
82.7M
↑ 10.95%
Q2 FY23Q/Q Change
Total Assets
418.9M
↑ 0.9%
Total Liabilities
80.0M
↓ 3.29%
Q3 FY23Q/Q Change
Total Assets
440.7M
↑ 5.19%
Total Liabilities
87.0M
↑ 8.72%
Q4 FY23Q/Q Change
Total Assets
471.5M
↑ 7.01%
Total Liabilities
92.9M
↑ 6.87%
Q1 FY24Q/Q Change
Total Assets
488.7M
↑ 3.64%
Total Liabilities
102.7M
↑ 10.56%
FY19Y/Y Change
Operating Cash Flow
12.8M
↑ 347.49%
Investing Cash Flow
-2.2M
↑ 114.63%
Financing Cash Flow
74.6M
↑ 2962.74%
FY20Y/Y Change
Operating Cash Flow
25.8M
↑ 102.04%
Investing Cash Flow
-10.2M
↑ 353.36%
Financing Cash Flow
149.0K
↓ 99.8%
FY21Y/Y Change
Operating Cash Flow
21.0M
↓ 18.78%
Investing Cash Flow
-8.4M
↓ 17.43%
Financing Cash Flow
19.6M
↑ 13034.9%
FY22Y/Y Change
Operating Cash Flow
44.0M
↑ 109.83%
Investing Cash Flow
-13.6M
↑ 62.36%
Financing Cash Flow
17.8M
↓ 9.08%
FY23Y/Y Change
Operating Cash Flow
35.7M
↓ 18.76%
Investing Cash Flow
-156.4M
↑ 1046.03%
Financing Cash Flow
8.3M
↓ 53.37%
Q4 FY22Q/Q Change
Operating Cash Flow
24.1M
↑ 82.01%
Investing Cash Flow
-46.7M
↑ 786.3%
Financing Cash Flow
5.0M
↑ 126.28%

Technicals Summary

Sell

Neutral

Buy

Staar Surgical Co is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Staar Surgical Co
Staar Surgical Co
28.62%
23.34%
-29.99%
-64.7%
50.42%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-4.26%
40.66%
27.13%
29.92%
117.28%
Resmed Inc.
Resmed Inc.
-4.93%
30.8%
-18.9%
-12.86%
79.74%
Becton, Dickinson And Company
Becton, Dickinson And Company
-3.24%
-8.51%
-10.39%
-9.17%
-1.52%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-0.68%
7.75%
8.05%
19.64%
215.5%
Alcon Ag
Alcon Ag
-4.1%
12.21%
10.64%
4.52%
37.47%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Staar Surgical Co
Staar Surgical Co
112.07
112.07
-4.89
1.04
0.06
0.04
NA
7.91
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
68.07
68.07
7.13
6.28
0.16
0.08
NA
39.37
Resmed Inc.
Resmed Inc.
30.5
30.5
1.75
7.4
0.22
0.11
0.01
30.47
Becton, Dickinson And Company
Becton, Dickinson And Company
53.75
53.75
1.34
12.95
0.05
0.03
0.02
87.68
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
49.52
49.52
6.72
7.62
0.21
0.12
0.0
39.2
Alcon Ag
Alcon Ag
41.2
41.2
4.59
3.06
0.05
0.02
0.0
41.81
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Staar Surgical Co
Staar Surgical Co
Buy
$2.4B
50.42%
112.07
6.62%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$133.8B
117.28%
68.07
27.16%
Resmed Inc.
Resmed Inc.
Buy
$27.1B
79.74%
30.5
19.77%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.7B
-1.52%
53.75
6.44%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$28.6B
215.5%
49.52
20.12%
Alcon Ag
Alcon Ag
Buy
$39.9B
37.47%
41.2
10.3%

Institutional Holdings

  • BROADWOOD CAPITAL Inc

    21.56%

  • BlackRock Inc

    16.70%

  • Vanguard Group Inc

    11.19%

  • Baillie Gifford & Co Limited.

    9.10%

  • State Street Corporation

    3.96%

  • Jackson Square Partners, LLC

    3.47%

Company Information

staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl"​. nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad

Organization
Staar Surgical Co
Employees
1056
CEO
Mr. Thomas G. Frinzi
Industry
Health Technology

Discover More

FAQs